Triaziquone

Triaziquone

SCHEMBL1869724

O=C1C=C(N2CC2)C(=O)C(N2CC2)=C1N1CC1.O=S(=O)(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.38
MAPT P10636 2/20 0.36
HTT P42858 2/20 0.36
TP53 P04637 1/20 0.36
STAT3 P40763 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
APAF1 O14727 2/20 0.32
TDP2 O95551 2/20 0.32
NSD2 O96028 2/20 0.32
HKDC1 Q2TB90 2/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
HIF1A Q16665 1/20 0.31
KMT2A Q03164 2/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triaziquone SCHEMBL6272818 0.88 DNMT1 (0.39) DNMT1MAPTHTTSMN1; SMN2APAF1
Triaziquone SCHEMBL895712 0.88 DNMT1 (0.43) DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL22361758 0.87 MAPT (0.39) DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL9791390 0.86 DNMT1 (0.42) DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL17698632 0.85 HTT (0.38) DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL19715926 0.85 DNMT1 (0.37) DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL108508 0.84 DNMT1 (0.41) DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL8303 0.84 DNMT1 (0.48) DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL1462397 0.83 DNMT1 (0.38) DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL15269829 0.82 DNMT1 (0.37) DNMT1MAPTHTTTP53STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3911657-A1 PROCESS FOR CONVERTING ORGANOSILANES Wacker Chemie AG (DE) 2021-11-24 EP claimed
CN-107207404-B Compound, and separation method, synthesis method and application thereof 北京北大维信生物科技有限公司 2021-07-13 CN claimed
CN-113004235-A Stereoselective synthesis method of (Z) -3-alkenyl phthalide derivative 中国医学科学院药物研究所 2021-06-22 CN claimed
WO-2021004648-A1 PROCESS FOR CONVERTING ORGANOSILANES WACKER CHEMIE AG (DE) 2021-01-14 WO claimed
EP-1694628-B1 PROCESS FOR THE MANUFACTURE OF TRIMETHYLHYDROQUINE DIALKANOATES DSM IP ASSETS BV (NL) 2011-08-31 EP claimed
US-20110144358-A1 Process for the manufacture of trimethylhydroquinone dialkanoates DSM IP ASSETS B.V. (NL) 2011-06-16 US claimed
JP-2007516262-A 2007-06-21 JP claimed
US-20070049762-A1 Process for the manufacture of trimethylydroquine dialkanoates DSM IP ASSETS B.V. (NL) 2007-03-01 US claimed
EP-1694628-A1 PROCESS FOR THE MANUFACTURE OF TRIMETHYLHYDROQUINE DIALKANOATES DSMIP Assets B.V. (NL) 2006-08-30 EP claimed
WO-2005058792-A1 PROCESS FOR THE MANUFACTURE OF TRIMETHYLHYDROQUINE DIALKANOATES DSM IP ASSETS B.V. (NL) 2005-06-30 WO claimed
CN-113454094-B Method for converting organosilanes 瓦克化学股份公司 2024-03-22 CN disclosed
CN-117561623-A Secondary battery, manufacturing method thereof, battery module, battery pack and power utilization device 宁德时代新能源科技股份有限公司 2024-02-13 CN disclosed
CN-116273169-A Supported catalyst and preparation method thereof 安庆莱霆光电科技有限公司 2023-06-23 CN disclosed
CN-116283520-A Preparation method of aryl ketone, alpha-hydroxy ketone and alpha-amino ketone 安庆莱霆光电科技有限公司 2023-06-23 CN disclosed
CN-113004235-B Stereoselective synthesis method of (Z) -3-alkenylphthalide derivative 中国医学科学院药物研究所 2023-05-05 CN disclosed
US-20020172885-A1 Novel carbazole derivative and chemically amplified radiation-sensitive resin composition JSR CORPORATION (JP) 2002-11-21 US disclosed
EP-1238972-A1 Novel carbazole derivative and chemically amplified radiation-sensitive resin composition JSR Corporation (JP) 2002-09-11 EP disclosed
US-20010041769-A1 Polysiloxane, method of manufacturing same, silicon-containingalicyclic compouns, and radiation-sensitive resin composition JSR CORPORATION (JP) 2001-11-15 US disclosed
EP-1142928-A1 Polysiloxane, method of manufacturing same, silicon-containing alicyclic compound, and radiation-sensitive resin compounds JSR Corporation (JP) 2001-10-10 EP disclosed
CN-1227556-A Process for preparation of hexanitrohexaazaiso wurtzitanes ASAHI CHEMICAL IND (JP) 1999-09-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020172885-A1 Novel carbazole derivative and chemically amplified radiation-sensitive resin composition ARID2, RAD1, RAD51 DNMT1 369/4885MAPT 3939/4885HTT 3475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.